Eric H. Westin

4.3k total citations · 2 hit papers
66 papers, 3.6k citations indexed

About

Eric H. Westin is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, Eric H. Westin has authored 66 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Molecular Biology, 21 papers in Oncology and 14 papers in Genetics. Recurrent topics in Eric H. Westin's work include Chronic Lymphocytic Leukemia Research (13 papers), T-cell and Retrovirus Studies (8 papers) and Acute Lymphoblastic Leukemia research (8 papers). Eric H. Westin is often cited by papers focused on Chronic Lymphocytic Leukemia Research (13 papers), T-cell and Retrovirus Studies (8 papers) and Acute Lymphoblastic Leukemia research (8 papers). Eric H. Westin collaborates with scholars based in United States, Spain and Australia. Eric H. Westin's co-authors include Flossie Wong‐Staal, Robert C. Gallo, Alessandra Eva, Michael F. Clarke, S A Aaronson, I. David Goldman, E. Premkumar Reddy, Takis S. Papas, Steven R. Tronick and Edward V. Prochownik and has published in prestigious journals such as Nature, Science and Proceedings of the National Academy of Sciences.

In The Last Decade

Eric H. Westin

66 papers receiving 3.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Expression of cellular homologues of retroviral onc genes in human hematopoietic cells.

1982 497 citations Eric H. Westin et al. profile →
Cellular genes analogous to retroviral onc genes are transcribed in human tumour cells

1982 433 citations Eric H. Westin et al. profile →

Peers

Countries citing papers authored by Eric H. Westin

Since Specialization

Citations

This map shows the geographic impact of Eric H. Westin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric H. Westin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric H. Westin more than expected).

Fields of papers citing papers by Eric H. Westin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric H. Westin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric H. Westin. The network helps show where Eric H. Westin may publish in the future.

Co-authorship network of co-authors of Eric H. Westin

This figure shows the co-authorship network connecting the top 25 collaborators of Eric H. Westin. A scholar is included among the top collaborators of Eric H. Westin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric H. Westin. Eric H. Westin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Population pharmacokinetics of mirvetuximab soravtansine in patients with folate receptor‐α positive ovarian cancer: The antibody–drug conjugate, payload and metabolite 2023 ·British Journal of Clinical Pharmacology ·Ya‐Ping Tu, (unknown), (unknown), H. Maxime Lagraauw, Callum M. Sloss, Michael Method, Brooke Esteves, Eric H. Westin, Anna Berkenblit	5
2	A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid Malignancies 2017 ·Clinical Cancer Research ·Dejan Juric, Johann S. de Bono, Patricia LoRusso, John Nemunaitis, Elisabeth I. Heath, Eunice L. Kwak, T. Macarulla Mercadé, Elena Geuna, Maria J. de Miguel, Chirag Patel, Keisuke Kuida, Serap Sankoh, Eric H. Westin, Fabian Zohren, Yaping Shou, Josep Tabernero	76
3	Two Phase 1 dose-escalation studies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer 2017 ·Cancer Chemotherapy and Pharmacology ·Jeffrey R. Infante, Amita Patnaik, Claire F. Verschraegen, Anthony J. Olszanski, Montaser Shaheen, Howard A. Burris, Anthony W. Tolcher, Kyriakos P. Papadopoulos, Muralidhar Beeram, Scott M. Hynes, Jennifer Leohr, Aimee Bence Lin, Lily Q. Li, Anna McGlothlin, Daphne L. Farrington, Eric H. Westin, Roger B. Cohen	29
4	A Novel Eg5 Inhibitor (LY2523355) Causes Mitotic Arrest and Apoptosis in Cancer Cells and Shows Potent Antitumor Activity in Xenograft Tumor Models 2015 ·Molecular Cancer Therapeutics ·Xiang S. Ye, Fan Li, Robert D. Van Horn, Ryuichiro Nakai, Yoshihisa Ohta, Shiro Akinaga, Chikara Murakata, Yoshinori Yamashita, Tinggui Yin, Kelly M. Credille, Gregory P. Donoho, Farhana F. Merzoug, Heng Li, Amit Aggarwal, Kerry Blanchard, Eric H. Westin	29
5	Abstract A49: Circulating tumor cell (CTC) assay development for detection of H2AX as a clinical pharmacodynamic (PD) marker for Chk1 kinase inhibitors. 2011 ·Molecular Cancer Therapeutics ·Victoria L. Peek, Suzane L. Um, S. Betty Yan, Lei Yan, Jack Dempsey, Darlene Barnard, (unknown), Darryl Ballard, Kathleen M. Heinz-Taheny, Mark S. Marshall, Richard P. Beckmann, Aimee K. Bence, Eric H. Westin	1
6	Lymphoma and myeloma in older patients 2004 ·Seminars in Oncology ·Eric H. Westin	18
7	Predictors of weight gain and cardiovascular risk in a cohort of racially diverse kidney transplant recipients 2002 ·Nutrition ·Charles L. Baum, (unknown), Eric H. Westin, (unknown), Luca Cicalese, E. Benedetti	59
8	Src can regulate carboxy terminal interactions with AFAP-110, which influence self-association, cell localization and actin filament integrity 1998 ·Oncogene ·Yong Qian, Joseph M. Baisden, Eric H. Westin, (unknown), (unknown), Daniel C. Flynn	46
9	G1 cell cycle arrest and apoptosis are induced in NIH 3T3 cells by KN-93, an inhibitor of CaMK-II (the multifunctional Ca2+/CaM kinase). 1995 ·PubMed ·Robert M. Tombes, Stephen R. Grant, Eric H. Westin, Gerald Krystal	106
10	Increased expression and characterization of two distinct folate binding proteins in murine erythroleukemia cells 1994 ·Biochemical Pharmacology ·Kevin E. Brigle, Michael J. Spinella, Eric H. Westin, I. David Goldman	65
11	Characterization of a rearrangement in the c-MYB promoter in the acute lymphoblastic leukemia cell line CCRF-CEM 1994 ·Cancer Genetics and Cytogenetics ·Sarah Jacobs, Karen Gorse, (unknown), Eric H. Westin	6
12	Expression of c-kit by mesenteric lymph node cells from Nippostrongylus brasiliensis-infected mice and by mast cell colonies developing from these cells in response to 3T3 fibroblast-conditioned medium 1992 ·The Journal of Immunology ·(unknown), Eric H. Westin, Thomas Huff	5
13	Malignant transformation of NIH 3T3 fibroblasts by human c‐sis is dependent upon the level of oncogene expression 1992 ·Molecular Carcinogenesis ·Linda MacArthur, Michael F. Clarke, Eric H. Westin	6
14	In vitro effects of bryostatin 1 on the metabolism and cytotoxicity of 1-β-d-arabinofuranosylcytosine in human leukemia cells 1991 ·Biochemical Pharmacology ·Steven Grant, Lawrence Boise, Eric H. Westin, Craig Howe, George R. Pettit, Amy Turner, Carl W. McCrady	18
15	A method for the synchronization of cultured cells with aphidicolin: Application to the large-scale synchronization of L1210 cells and the study of the cell cycle regulation of thymidylate synthase and dihydrofolate reductase 1989 ·Analytical Biochemistry ·Larry H. Matherly, John D. Schuetz, Eric H. Westin, I. David Goldman	49
16	Coordination and reversibility of signals for proliferative activation and interleukin-2 mRNA production in resting human T lymphocytes by phorbol ester and calcium ionophore. 1988 ·Journal of Biological Chemistry ·Carl W. McCrady, Constance M. Ely, Eric H. Westin, Richard A. Carchman	31
17	Minimal change in transport and growth requirement for folic acid fa in an l1210 leukemia cell line with markedly impaired transport of methotrexate mtx 1988 ·(unknown), John D. Schuetz, Richard L. Seither, Eric H. Westin, I. David Goldman	3
18	Constitutive Expression of a c- myb cDNA Blocks Friend Murine Erythroleukemia Cell Differentiation 1988 ·Molecular and Cellular Biology ·Michael F. Clarke, (unknown), Eric H. Westin, Michael J. Smith, Edward V. Prochownik	61
19	Use of phorbol-12,13-dibutyrate as a mitogen in the cytogenetic analysis of tumors with low mitotic indexes 1988 ·Cancer Genetics and Cytogenetics ·(unknown), (unknown), A. Scott Mills, J.A. Brown, Eric H. Westin	8
20	Allelic variation of the c-raf-1 oncogene in non-Hodgkin's lymphoma. 1987 ·PubMed ·Georgia Chenevix‐Trench, F G Behm, Eric H. Westin	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact